Clinical features of essential thrombocythaemia with coexisting JAK2 V617F and CALR mutations: a multicentre retrospective study in China

JAK2 V617F, CALR and MPL mutations are treated as mutually exclusive in essential thrombocythaemia (ET), and testing usually stops once JAK2 V617F is found. Coexisting mutations cluster at a low JAK2 allele burden, but whether they define a distinct phenotype in Chinese patients is unresolved. We compared 24 Chinese patients with coexisting JAK2 V617F and CALR mutations, nine of them identified from published reports, with 110 patients with isolated JAK2 V617F and 21 with an isolated CALR mutation, and analysed phenotype, allele burdens, revised IPSET-thrombosis categories, treatment and transformation with permutation testing, Holm-Bonferroni correction and competing-risk analysis. Co-mutated patients had higher haemoglobin (12 g/L, 95% confidence interval 3–23) and more splenomegaly (55.0% versus 24.3%), both borderline after correction (adjusted P = .051 and .054), together with a lower JAK2 V617F burden (22.4% versus 27.0%; below 5% in 3 of 13 versus 3 of 65). Two thirds (66.7%) were classified as high risk because the revised International Prognostic Score of thrombosis counts JAK2 positivity alone. Thrombotic risk could not be assessed, since a thrombosis field was recorded for only six CALR-mutated controls. Transformation was more frequent in co-mutated patients in both analyses (12.5% and 20.0% versus 3.6%), but the significance was not stable (P = .111 and .038). Coexisting mutations therefore mark a phenotype that leans towards JAK2-mutated ET without a confirmed excess of thrombotic or transformative risk, and CALR exon 9 should be tested whenever JAK2 V617F is present.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11432430/v1
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical features of essential thrombocythaemia with coexisting JAK2 V617F and CALR mutations: a multicentre retrospective study in China

申徐良, Meixiang Zhang, Lu Dong, Xiaocai MA et al.
Research Square
Myeloproliferative Neoplasms: Diagnosis and Treatment
preprint

Clinical features of essential thrombocythaemia with coexisting JAK2 V617F and CALR mutations: a multicentre retrospective study in China

申徐良, Meixiang Zhang, Lu Dong, Xiaocai MA, Hu Wenqing, Qinlong Zheng, Jian xin Liu
preprint en

Abstract

JAK2 V617F, CALR and MPL mutations are treated as mutually exclusive in essential thrombocythaemia (ET), and testing usually stops once JAK2 V617F is found. Coexisting mutations cluster at a low JAK2 allele burden, but whether they define a distinct phenotype in Chinese patients is unresolved. We compared 24 Chinese patients with coexisting JAK2 V617F and CALR mutations, nine of them identified from published reports, with 110 patients with isolated JAK2 V617F and 21 with an isolated CALR mutation, and analysed phenotype, allele burdens, revised IPSET-thrombosis categories, treatment and transformation with permutation testing, Holm-Bonferroni correction and competing-risk analysis. Co-mutated patients had higher haemoglobin (12 g/L, 95% confidence interval 3–23) and more splenomegaly (55.0% versus 24.3%), both borderline after correction (adjusted P = .051 and .054), together with a lower JAK2 V617F burden (22.4% versus 27.0%; below 5% in 3 of 13 versus 3 of 65). Two thirds (66.7%) were classified as high risk because the revised International Prognostic Score of thrombosis counts JAK2 positivity alone. Thrombotic risk could not be assessed, since a thrombosis field was recorded for only six CALR-mutated controls. Transformation was more frequent in co-mutated patients in both analyses (12.5% and 20.0% versus 3.6%), but the significance was not stable (P = .111 and .038). Coexisting mutations therefore mark a phenotype that leans towards JAK2-mutated ET without a confirmed excess of thrombotic or transformative risk, and CALR exon 9 should be tested whenever JAK2 V617F is present.

Research Square
Changzhi Medical College (CN), Peking University International Hospital (CN), Peking University Shougang Hospital (CN)
Peking University
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon